Isolation and characterization of aclacinomycin A-non-producing Streptomyces galilaeus (ATCC 31615) mutants.
Twelve mutants of Streptomyces galilaeus (ATCC 31615) blocked in the production of aclacinomycin A, an anthracycline antibiotic with significant antitumour activity, accumulated intermediates of the biosynthesis of aclacinomycins and several anthracyclines with variant sugar moieties. Three of these aklavinone glycosides have not been described before. Mutant strains H028, H061 and H036 were blocked before the formation of aklavinone, a common intermediate for most anthracyclines. Strain H039 accumulated aklavinone and H026, H035, H038 and H054 had mutations that changed glycosylation of aklavinone. Characterization of the mutants and their products is described.
Ylihonko
K
K
Department of Biochemistry and Food Chemistry, University of Turku, Finland.
Hakala
J
J
Niemi
J
J
Lundell
J
J
Mäntsälä
P
P
D000085:Acetates / Q000378:metabolism; D015250:Aclarubicin / Q000031:analogs & derivatives* / Q000096:biosynthesis; D000880:Anthraquinones / Q000378:metabolism; D002240:Carbohydrate Sequence; D002241:Carbohydrates / Q000737:chemistry; D008969:Molecular Sequence Data; D015394:Molecular Structure; D016296:Mutagenesis; D009279:Naphthacenes / Q000378:metabolism; D011422:Propionates / Q000378:metabolism; D013302:Streptomyces / Q000235:genetics* / Q000378:metabolism
D000085:Acetates; D000880:Anthraquinones; D002241:Carbohydrates; D009279:Naphthacenes; D011422:Propionates; C011157:aclacinomycins; C027832:aklavinone; D015250:Aclarubicin; C042374:aklanonic acid; C029658:propionic acid